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http://dx.doi.org/10.1016/j.jmii.2013Background/Purpose: Infectious disease physicians (IDPs) play a major role in patient care, in-
fectious disease control, and antibiotic use in hospitals. The aim of this research is to explore
the effects of employment of IDPs on patients’ prognosis and the related medical and antibi-
otic expenses in hospitals.
Methods: This population-based study provides evidence-based information on IDPs’ contribu-
tion to patients’ prognosis and antibiotic expenditure containment with inpatient claim data
from the Taiwan Bureau of National Health Insurance in 2004. We further classified regional
hospitals into those with and without IDPs and analyzed patient prognosis, length of stay, total
medical expenses, and antibiotic expenses to test the effects of IDPs.
Results: The likelihood of developing a poor prognosis among patients was found to be higher
in non-IDP hospitals, with an odds ratio of 1.14 and a 95% confidence interval of 1.05e1.23
(p Z 0.002). Medical expenses, excluding those of nonrestricted drugs, were found to bewa 1st Road, Kwei-Shan, Taoyuan 333, Taiwan.
u.tw (K.-H. Hsu).
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298 C.-P. Shih et al.higher in the non-IDP group than in the IDP group. The total medical expenses were also found
to be 10% higher in the non-IDP group than in the IDP group (p < 0.001).
Conclusion: Employment of IDPs was likely to improve patient prognosis and reduce
overall medical expenses. It is suggested that healthcare administrators consider the
employment of or investment in IDPs as a cost-effective strategy for improving patient quality
of care.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The major responsibilities of infectious disease physicians
(IDPs) are patient care, nosocomial infection control,
antibiotic management, and infectious disease education
and consultation.1 However, it is difficult to quantitatively
evaluate these responsibilities and the performance and
workload of IDPs are not properly evaluated in most
healthcare settings. In addition, there are insufficient data
for hospital administrators to justify employing IDPs.
IDPs play a role in internal quality control in a medical
setting. Previous research has indicated that the contribu-
tions of IDPs included their role in maintaining medical
quality and reducing hospital medical expenses.2 The role
of IDPs was also revealed by a cost-effectiveness analysis of
the placement of these professionals and its effect on the
outcomes of clinical care.3 Studies demonstrated that IDPs
tended to discharge patients more easily than general in-
ternal medicine practitioners, and they were more likely to
prescribe oral instead of injectable antibiotics for patients
who were discharged earlier.4,5 In addition, IDPs could also
reduce the likelihood of nosocomial infection through the
use of appropriate antibiotics. Nosocomial infections can
prolong hospital length of stay (LOS) and increase medical
costs.6 Previous costebenefit analyses showed infection
control programs were beneficial.7,8 More severely ill pa-
tients benefitted the most from infection control programs
accompanied by infectious disease specialty consultation.9
Overall, nosocomial infection control was identified as an
important factor to reduce medical costs, LOS, and in-
hospital mortality.6 However, the global effect of IDPs on
patients’ medical outcomes remains unclear.
Better diagnoses and prognoses for patients treated by
IDPs were found in some specific types of infections, such as
sepsis,10 endocarditis,11 and human immunodeficiency
virus/acquired immunodeficiency syndrome.12 The IDPs
were able to modify antibiotic prescriptions and used more
specific antibiotics following culture results.13,14 There-
fore, IDPs were more likely to prescribe the correct anti-
biotics than other specialties.
The employment of IDPs is not universally accepted as
beneficial in many healthcare systems due to the uncertain
effects on healthcare quality and medical expenses in
countries such as Taiwan. However, the uneven employ-
ment of IDPs in regional hospitals in Taiwan offers the op-
portunity to examine their effects. The aim of this research
was to explore the effects of employment of IDPs on pa-
tient prognoses and related medical and antibiotic ex-
penses in hospitals.Methods
Database and study samples
The study database is a 5% systematic sample of inpatient
claims from the Bureau of National Health Insurance in
Taiwan in 2004. A total of 57,829 inpatients in regional
hospitals were used as the base study population in this
analysis.
Regional hospitals were chosen because of their diverse
employment of IDPs, optimal size and number of beds, and
homogeneous case mix of patients. Hospitals employing
IDPs during the study period, as indicated by insurance
claims relating to infectious diseases, were classified as
having IDPs. Regional hospitals with service volumes below
the 25th percentile or above the 75th percentile were
excluded in order to control for the skewness of resource
allocation and the employment of IDPs in hospitals with
different service volumes. In Taiwan, few small hospitals
(below the 25th percentile) but most large hospitals (above
the 75th percentile) employ IDPs. The study only included
patients 18 years of age or older because the use of anti-
biotics in adults differs from that in children. We grouped
hospitals, which included a total of 26,483 hospitalized
patients, into those with and without IDPs. The data from
these two groups were analyzed for differences between
the groups of hospitals regarding medical expenses, drug
expenses, antibiotic expenses, patient treatment out-
comes, and LOS.Variables of interest
In this study, antibiotic prescription was limited to
treatment for bacterial infections; antituberculosis,
antiviral, antifungal, and parasitic medications were
excluded. We also limited the type of antibiotic admin-
istration to the oral and injection routes and excluded
eye drops, ear fluid, plug agents, and skin cream
applications.
The purpose of this study is twofold. The first is to
compare basic characteristics, including defined daily dose
(DDD), total inpatient beds, and total annual inpatient
claims, between hospitals with and without IDPs. DDD is
defined as “the assumed average maintenance dose per
day for a drug used for its main indication in adults”.15 The
second is to compare patients’ medical outcomes and
medical consumptions between groups with and without
IDPs. Disease complexity is represented by the Charlson
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defined using the International Classification of Diseases,
Ninth Edition, Clinical Modification (ICD-9-CM) diagnosis
codes and are weighted from 1 to 6, on the basis of the
relative risk of dying from the condition.16 The overall
complexity score was calculated by adding together all
individual complexity scores for a given patient in this
study. We defined treatment outcomes using information in
the discharge records which described the physical condi-
tions and clinical manifestations of patients. Treatment
discharge and transfer to outpatient clinic visits were
considered improved outcomes, while death, discharge
with critical conditions against medical advice, and trans-
fer to other medical institutions for continuing treatment
were considered poor outcomes.
Medical consumptions included LOS and medical
expenses, which consisted of total medical expenses,
total drug expenses, total antibiotic expenses, oral
antibiotic expenses, injected antibiotic expenses, unre-
stricted antibiotic expenses, and restricted antibiotic
expenses.
Statistical analyses
Results for medical expenses and LOS are given as numer-
ical variables with means and standard deviation. Fre-
quency and percentage were used to describe categorical
variables such as treatment outcomes.
Medical expenses and LOS were logarithmically trans-
formed due to a right skewed distribution for subsequent
statistical analyses. Two independent sample t tests were
used to compare the difference in continuous variables
between study groups. The Wilcoxon rank-sum test was also
used to compare the difference in continuous variables
without logarithmic transformation between the two studyTable 1 Descriptive characteristics of the study hospitals
Variables IDPs (n Z 1
Mean  SD
Defined daily doses (1000 person/d) 0.46  0.60
Total inpatient beds 1040  456
Total annual inpatient claims 17,194  31
Medical departments
Family medicine 18 (6.6%)
General medicine 19 (7.0%)
Surgery 19 (7.0%)
Pediatrics 19 (7.0%)
Obstetrics and gynecology 19 (7.0%)
Othersd 179 (65.6%)
Physician age 41.7  7.3
Physician sex
Male 1079 (88.7%
Female 137 (11.3%)
a Calculated using the Wilcoxon rank-sum test.
b Calculated using a two-sample t test.
c Calculated using the c2 test.
d Including departments of orthopedics, neurosurgery, urology, otol
and plastic surgery.
IDPs Z infectious disease physicians; SD Z standard deviation.groups. The c2 test was applied to examine the association
of data with categorical variables in the two hospital
groups. Furthermore, a multiple logistic regression and
general linear model was used for multivariable analysis on
treatment outcomes and on medical consumptions while
adjusting for other confounding variables. Regression di-
agnostics, including residual analysis, outlier diagnosis by
Cook distance, and collinearity analysis by variance infla-
tion factor and conditional index, were performed to check
the appropriateness of the final regression models.
Statistical Analysis System software version 9.2 for
Windows (SAS Institute, Cary, North Carolina, USA) was
used for data analyses.
Results
Regional hospital data from national health insurance re-
cords in Taiwan were collected for a nationwide evidence-
based analysis. In the first phase of the analysis, there were
19 regional hospitals with IDPs (intervention group; IDPs)
and 18 regional hospitals without IDPs (control group; non-
IDPs). Basic characteristics, including DDD, total inpatients
beds, total annual inpatient claims, medical departments,
and physicians’ age and sex, were compared but no sig-
nificant differences between the two study groups were
found. The DDD was 0.46  0.60 in IDPs and 0.84  1.35 in
non-IDPs (p Z 0.29). The total number of inpatients beds
was 1040  456 for IDPs and 925  235 for non-IDPs
(p Z 0.34). The total number of annual inpatient claims
was 17,194  3135 and 17,191  3008 in IDPs and non-IDPs,
respectively (p Z 1.0). The distribution of major de-
partments was similar between the two study groups
(p Z 1.0). Physician age was also similar in IDPs and non-
IDPs (41.7  7.3 years of age and 41.4  7.3 years of age,
respectively; p Z 0.39). Most of the physicians were male9) Non-IDPs (n Z 18) p
Mean  SD
0.84  1.35 0.29a
925  235 0.34b
35 17,191  3008 1.00b
18 (7.0%) 1.00
18 (7.0%)
18 (7.0%)
18 (7.0%)
18 (7.0%)
169 (65.3%)
41.4  7.3 0.39b
) 948 (89.9%) 0.39c
107 (10.1%)
aryngology, ophthalmology, neurology, psychiatry, rehabilitation,
300 C.-P. Shih et al.in the IDP and non-IDP groups (88.7% and 89.9%, respec-
tively; p Z 0.39) (Table 1).
In the second phase of analysis, 13,768 patients and
12,715 patients were included in the IDP and non-IDP
groups, respectively. Average patient age was 54.0 years
and 55.1 years in the IDP and non-IDPs groups, respectively
(p < 0.001). There were similar proportions of male and
female patients in the two groups (p Z 0.53). The per-
centage of patients with poor treatment outcomes was
higher in the non-IDP group, (13.24%) than in the IDP group
(11.66%; p < 0.001). Analysis of the Charlson score found
more patients in the IDP group than in the non-IDP group
had a higher score (p < 0.001). Antilogarithmic trans-
formation showed the total medical expenses per patient
were 819.6 USD in IDPs and 914.9 USD in non-IDPs
(p < 0.001). Furthermore, the non-IDPs group had signifi-
cantly higher expenses for items such as antibiotics, oral
antibiotics, injectable antibiotics, and restricted antibi-
otics (Table 2).
The likelihood of developing poor treatment outcomes
among patients was found to be higher in non-IDP hospitalsTable 2 Demographics, clinical variables, and medical consum
IDPs group
Study patients, n 13,768
Average patient aged 54.0  19.9
Patient sex
Male 7169 (52.07%)
Female 6494 (47.17%)
Unreported 105 (0.76%)
Treatment outcomes
Poor 1605 (11.66%)
Improved 12,163 (88.34%)
Charlson score
0 7323 (53.19%)
1 2302 (16.72%)
2 2143 (15.57%)
3 2000 (14.53%)
Total medical expenses (USD)e 819.6  0.2
Median (Q1, Q3) 925.8 (524.5, 1737
Drug expenses (USD)e 61.5  0.2
Median (Q1, Q3) 70.4 (25.9, 200.9)
Antibiotic expenses (USD)e 2.4  1.3
Median (Q1, Q3) 6.8 (0.0, 55.6)
Oral antibiotic expenses (USD)d 0.24  0.4
Median (Q1, Q3) 0.0 (0.0, 3.0)
Injectable antibiotic expenses (USD)d 1.52  1.5
Median (Q1, Q3) 3.4 (0.0, 50.8)
Unrestricted antibiotic expenses (USD)d 1.42  1.0
Median (Q1, Q3) 3.7 (0.0, 37.8)
Restricted antibiotic expenses (USD)d 0.12  0.7
Median (Q1, Q3) 0.0 (0.0, 0.0)
Length of stayd 9.1  12.5
Median (Q1, Q3) 5 (3, 10)
a Calculated by a two-sample t test after logarithmic transformatio
b Calculated by a two-sample t test.
c Calculated by the c2 test.
d Mean  standard deviation USD.
e Calculated by the Wilcoxon rank-sum test.
IDPs Z infectious disease physicians; QZquartile.with an odds ratio (OR) of 1.14 and a 95% confidence in-
terval (CI) of 1.05e1.23 (p Z 0.002). An increased likeli-
hood of developing poor treatment outcomes was found in
the non-IDP group as opposed to the IDP group among the
strata of patients age 18e65 years (ORZ 1.22, p < 0.001),
Charlson score Z 0 (OR Z 1.44, p < 0.001) (Table 3).
The medical expenses of patients in the two hospital
groups were analyzed using a general linear model.
Medical expenses, excluding nonrestricted drugs, were
generally higher in the non-IDP group than in the IDP
group. Antilogarithmic transformation showed that the
total medical expenses per patient were 713.5 USD in the
non-IDP group, which is higher than the 641.7 USD in the
IDP group (p < 0.001). The antilogarithmically transformed
overall drug expenses and restricted drug expenses were
found to be higher in the non-IDP group than in the IDP
group (55.8 USD vs. 55.3 USD, p < 0.01; 0.32 USD vs. 0.27
USD, p < 0.001, respectively). However, the unrestricted
drug expenses were found to be higher in the IDP group
than in the non-IDP group (1.2 USD vs. 1.1 USD; p < 0.01)
(Fig. 1).ptions of patients in the two study groups
Non-IDPs group p pe
12,715
55.1  19.9 <0.001b
0.53c
6567 (51.65%)
6062 (47.68%)
86 (0.68%)
<0.001c
1684 (13.24%)
11,031 (86.76%)
<0.001c
7003 (55.08%)
2398 (18.86%)
1647 (12.95%)
1667 (13.11%)
914.9  0.1 <0.001a 0.009
.1) 908.4 (504.9, 1678.8)
63.36  0.2 0.25a <0.001
64.4 (24.4, 181.2)
2.7  1.4 0.01a 0.003
8.5 (0.0, 62.4)
0.26  0.4 0.05a 0.08
0.0 (0.0, 3.0)
1.71  1.6 0.007a 0.003
3.5 (0.0, 57.2)
1.39  1.0 0.66a 0.60
3.4 (0.0, 36.1)
0.16  0.9 <0.001a <0.001
0.0 (0.0, 0.0)
9.0  12.4 0.72a 0.73
5 (3, 10)
n.
Table 3 Patient treatment outcomes between IDP and non-IDP groups stratified by various factors with multiple logistic
regression analyses
Sample Poor Improved Odds ratioa 95% CI of OR p
Overall patients
Non-IDP/IDP 1684/1605 (13.2%/11.7%) 11,031/12,163 (86.8%/88.3%) 1.14 1.05,1.23 0.002
Patient characteristics
Patient age older than 18 y, younger than 65 y
Non-IDP/IDP 866/853 (10.9%/9.5%) 7062/8157 (89.1%/90.5%) 1.22 1.09,1.36 <0.001
Patient age 65 y or older
Non-IDP/IDP 818/752 (17.1%/15.8%) 3969/4006 (82.9%/84.2%) 1.08 0.96,1.21 0.23
Patient disease complexity index
Charlson score Z 0
Non-IDP/IDPs 749/584 (10.7%/7.8%) 6254/6739 (89.3%/92.0%) 1.44 1.27,1.64 <0.001
Charlson score Z 1
Non-IDP/IDP 377/325 (15.7%/14.1%) 2021/1977 (84.3%/85.9%) 1.19 1.00,1.41 0.06
Charlson score  2
Non-IDP/IDP 558/696 (16.8%/16.8%) 2756/3447 (83.2%/83.2%) 0.90 0.79,1.03 0.13
a Adjusted using patient age, sex, major diagnosis, Charlson score, length of stay, hospital service volume, physician age, and physician
sex other than the stratified variable.
CI Z confidence interval; IDP Z infectious disease physician; OR Z odds ratio.
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Employment of IDPs could result in savings of 10% in med-
ical expenditure and improve prognosis without influencing
LOS. Previous studies have shown the positive effects of
infectious disease consultation on the patient’s clinical
outcome, including increased cure rate and decreased
recurrence rate of infection,17 shortened LOS, and reduced
mortality rate.9,18 The underlying reasons for the improved
outcomes were the higher chance of patients receiving
evidence-based management through infectious diseases
consultation19 and more appropriate antibiotic treatment
for their particular infection.18 In this study, we revealed
better patient outcomes in hospitals employing IDPs
compared with those that did not. The improvement in
patient outcomes as a result of IDP employment was found
in patients aged 18e65 years with a low Charlson score.Figure 1. Comparison of medical expenses of patients between
multivariable analysis (least-square adjustment was made by pati
Charlson score, treatment outcomes, service volume, physicia
IDPs Z infectious disease physicians.One explanation might be that adherence to IDPs’ recom-
mendations may result in early clinical improvements,
reduced in-hospital mortality, shortened LOS,20 and low-
ered comorbidity rate.17 Misuse or overuse of antibiotics
could cause antibiotic resistance,21 further resulting in a
high mortality rate, lengthened hospital stay, and increased
healthcare costs.22 The rate of adherence to IDP recom-
mendations was higher in private hospitals than in public
hospitals (87% vs. 74%), but was not related to physician
tenure.23 Patients who receive appropriate antibiotic
therapy may have better clinical outcomes such as reduced
duration of mechanical ventilation, less antibiotic therapy,
less intensive care unit (ICU) care, reduced LOS, reduced
ICU mortality, and a lower in-hospital mortality rate.19
Based on previously demonstrated mechanisms and the
findings of our study, it is suggested that a more careful
diagnostic process, the correct use of antibiotics, and IDP-the IDPs and non-IDPs groups with a general linear model of
ent age, patient sex, hospital length of stay, major diagnosis,
n age, and physician sex). ))p < 0.01; )))p < 0.001.
302 C.-P. Shih et al.assisted systems are likely to improve patient outcome. The
Charlson score in the IDP group was higher than that in the
non-IDP group. Further stratified analysis showed a statis-
tically significant difference in prognosis between study
groups in patients with lower Charlson scores (Charlson
score Z 0, p < 0.001; Charlson score Z 1, p Z 0.06). The
findings suggested that there was no difference in prognosis
among complicated cases, where there are additional fac-
tors such as therapies other than antibiotic administration
and irreversible health conditions. Conversely, the prog-
nosis of patients with less complicated conditions was
easily affected by factors such as appropriate antibiotic
usage and control.
Medical cost containment has become increasingly
important due to limited medical resources and strict
regulatory interventions under the global budget payment
system in Taiwan. Additional medical expenses due to
nosocomial infection had a different financial effect under
the previous fee-for-service system and the prospective
payment system. Decreased nosocomial infection could
improve the quality of patient care and reduce subse-
quent medical expenses.24 The prevention of nosocomial
infection through infection control could significantly
affect medical costs, LOS, and hospital mortality.6 In
addition, prevention of inappropriate antibiotic pre-
scriptions as a result of IDP supervision would decrease
medical expenses and avoid potential adverse effects.
Therefore, employing IDPs in hospitals could benefit both
patients and providers. In addition to demonstrating
improved patient prognosis, this study showed that
employing IDPs in hospital might help reduce total medical
expenses. The hospitals that employed IDPs had 10% lower
total medical expenses, 5% lower overall drug expenses,
and 18.5% lower restricted antibiotic drug expenses than
those hospitals not employing IDPs. The average differ-
ence in antibiotic expenses per case was 0.28 USD be-
tween the two study groups, while the overall difference
in antibiotic expenses between the two groups was 7,415
USD among the 5% samples of inpatient claims. A total
difference of 148,305 USD was found between the two
groups in the entire 529,660 adult patient population in
regional hospitals nationwide. Previous studies have
shown that intervention by an antibiotic management
team reduced medical costs, with the cost per patient-day
reducing from 18 USD to 14 USD in a 575-bed hospital,25 a
54% reduction in cumulative daily medical cost,26 a
322,000 USD annual cost savings in a 1200-bed hospital,27
and a 30.8% decrease in average intravenous antibiotic
expenses.28 Furthermore, the cost of 2,367 USD per
quality-adjusted life years gained has been shown to be
another important positive effect of an antibiotic man-
agement team on economic outcomes.7 A well-designed
antibiotic management team could improve patient
care, lower costs, and reduce the number of inappropriate
prescriptions.24 In this study, we were unable to show the
effects of appropriate treatment on infectious conditions
because efficacy, safety, and reasonable cost must also be
considered in the rational use of drugs.29 Although there
was insufficient information on efficacy and safety in this
study, we noticed a reverse association of restricted and
nonrestricted antibiotic prescriptions between IDPs and
non-IDPs. Strategies have been identified to minimizeinappropriate treatments, including consulting IDPs, dou-
ble-checking on prescriptions, and using antibiotic
practice guidelines.30 Furthermore, the appropriate pre-
scription rates of restricted antibiotics and unrestricted
antibiotics were shown in the literature to be 88.4% and
58.1%, respectively.27 Antibiotic expenses were decreased
by 18.5% after the introduction of an antibiotic restriction
policy regulated by IDPs.27 An antibiotic restriction policy
and consultation provided by IDPs could improve antibiotic
use and reduce antibiotic expense.
Employment of IDPs in regional hospitals in Taiwan could
be improved in many aspects: (1) the overall physician fees
are relatively less attractive to young physicians; (2) many
hospitals currently do not employ IDPs; (3) some hospitals
employ physicians with other specialties to act as IDPs,
which negatively effects the developments of IDPs; and (4)
many hospital administrators consider the employment of
IDPs as an item of expense, not profit. Using a national
database, this study has demonstrated cost savings and
quality improvement with the employment of IDPs, which
may lead to the re-evaluation of IDPs in the current
healthcare system, especially under prospective payment
systems. It is suggested to both policymakers and hospital
administrators that the employment of IDPs is cost-
effective and a positive costebenefit investment.
This study has six limitations. First, the effect of IDPs
was based on the existence in the hospital of a depart-
ment of infection control. In this study, we did not
measure the function or intensity of activities related to
antibiotic prescription control. Second, nondifferential
misclassification bias might exist as it is difficult to
determine efforts and practice patterns from the national
health database. If this misclassification exists, the ef-
fects shown in this study may be underestimated.
Accordingly, the difference in treatment outcomes and
medical expenses would be even higher between the two
study groups. In other words, the favorable effects of
employing IDPs in a hospital would be higher than
demonstrated. Third, although the patient profile was
corrected to some extent with Charlson scores in this
analysis, management systems and policy enforcement
were not measured. Therefore, adjustments were not
perfect. Fourth, any the incorrect reporting of prognosis
and medical expenses may have caused random error in
this study. Fifth, although confounding variables will
affect outcomes, the confounding effect was randomized
into study groups due to the large sample size in this
study. We do not know whether any other factors related
to employing IDPs among hospitals have affected the
outcomes of this study. We assume that the behavior of
employing IDPs is independent of medical outcomes.
Sixth, the effects of physician fee policy on prescription
behavior would have varied among regional hospitals.
However, we did not measure those effects.
In conclusion, the potential value of IDPs could be
justified based on the results of this study. It is suggested
that health policymakers reconsider the employment of
IDPs across different levels of hospitals, and managers
consider the employment of or investment in IDPs as a
cost-effective strategy for improving care quality. Further
studies are warranted to validate the findings of this
study.
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